Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 17/20 | 0.66 |
| ▸ | MAOA | P21397 | 3/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.56 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.52 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9946046 | 0.86 | MAOB (0.65) | MAOBMAOANR4A2PARP10 | |
| SCHEMBL4304772 | 0.86 | MAOB (0.63) | MAOBMAOANR4A2MRGPRX4PARP10 | |
| SCHEMBL9946047 | 0.84 | MAOB (0.62) | MAOBMAOANR4A2 | |
| SCHEMBL9946080 | 0.83 | MAOB (0.65) | MAOBMAOAACHE | |
| SCHEMBL16808917 | 0.80 | MAOB (0.71) | MAOBMAOANR4A2MRGPRX4ACHE | |
| SCHEMBL20098914 | 0.80 | MAOB (0.71) | MAOBMAOANR4A2MRGPRX4PARP10 | |
| SCHEMBL16710557 | 0.80 | MAOB (0.77) | MAOBMAOANR4A2MRGPRX4PARP10 | |
| SCHEMBL11959694 | 0.79 | MAOB (0.72) | MAOBMAOANR4A2PARP10 | |
| SCHEMBL9946045 | 0.78 | MAOB (0.64) | MAOBMAOA | |
| SCHEMBL21340832 | 0.78 | MAOB (0.79) | MAOBMAOANR4A2MRGPRX4PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | MAOB 780/4885MAOA 809/4885NR4A2 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.